Crinetics Pharmaceuticals (NASDAQ:CRNX – Get Free Report) and Sunshine Biopharma (NASDAQ:SBFM – Get Free Report) are both healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, valuation, risk, institutional ownership, dividends, profitability and earnings.
Earnings & Valuation
This table compares Crinetics Pharmaceuticals and Sunshine Biopharma”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Crinetics Pharmaceuticals | $7.70 million | 1,170.54 | -$465.32 million | ($5.04) | -16.86 |
| Sunshine Biopharma | $36.31 million | 0.09 | -$5.97 million | ($10.15) | -0.08 |
Profitability
This table compares Crinetics Pharmaceuticals and Sunshine Biopharma’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Crinetics Pharmaceuticals | -1,189.88% | -44.22% | -39.77% |
| Sunshine Biopharma | -17.94% | -26.36% | -20.60% |
Analyst Ratings
This is a breakdown of current ratings and price targets for Crinetics Pharmaceuticals and Sunshine Biopharma, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Crinetics Pharmaceuticals | 1 | 11 | 5 | 0 | 2.24 |
| Sunshine Biopharma | 1 | 1 | 1 | 0 | 2.00 |
Crinetics Pharmaceuticals presently has a consensus target price of $81.00, indicating a potential downside of 4.65%. Sunshine Biopharma has a consensus target price of $70.00, indicating a potential upside of 8,222.43%. Given Sunshine Biopharma’s higher probable upside, analysts plainly believe Sunshine Biopharma is more favorable than Crinetics Pharmaceuticals.
Insider & Institutional Ownership
98.5% of Crinetics Pharmaceuticals shares are held by institutional investors. Comparatively, 42.0% of Sunshine Biopharma shares are held by institutional investors. 3.8% of Crinetics Pharmaceuticals shares are held by insiders. Comparatively, 0.5% of Sunshine Biopharma shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Risk & Volatility
Crinetics Pharmaceuticals has a beta of 0.08, indicating that its share price is 92% less volatile than the S&P 500. Comparatively, Sunshine Biopharma has a beta of 1.17, indicating that its share price is 17% more volatile than the S&P 500.
Summary
Sunshine Biopharma beats Crinetics Pharmaceuticals on 8 of the 14 factors compared between the two stocks.
About Crinetics Pharmaceuticals
Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors. It is also developing CRN04894, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and Cushing's disease. In addition, the company is developing antagonists of the parathyroid hormone (PTH) receptor for the treatment of primary hyperparathyroidism and humoral hypercalcemia of malignancy, and other diseases of excess PTH; identified investigational orally available somatostatin receptor type 3 targeted nonpeptide agonists for the treatment of autosomal dominant polycystic kidney disease; and developing thyroid-stimulating hormone receptor antagonists for the treatment of graves' disease and thyroid eye disease, as well as Oral GLP-1 and GIP nonpeptides for the treatment of diabetes and obesity. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.
About Sunshine Biopharma
Sunshine Biopharma, Inc., a pharmaceutical company, focuses on the research and development of life-saving medicines in various therapeutic areas, including oncology and antivirals in the United States and Canada. It operates in two segments, Prescription Generic Pharmaceuticals and Nonprescription Over-The-Counter Products. The company is developing SBFM-PL4, a protease inhibitor for the treatment of SARS coronavirus infections; Adva-27a, a small chemotherapy molecule to treat pancreatic cancer; and K1.1 mRNA, a lipid nano-particle for liver cancer. It also offers Essential 9, an amino acids capsules; Calcium-Vitamin D supplement under the Essential Calcium-Vitamin D brand name; and L-Citrulline and Taurine products. In addition, the company provides various generic prescription drugs for osteoporosis, cardiovascular, antipsychotic, antibacterial, hypertension, anti-inflammatory, allergy, antibiotic, central nervous system, diabetes, urology, antifungal, antimalarial, oncology, gastroenterology, and anticonvulsant indications. Sunshine Biopharma, Inc. is headquartered in New York, New York.
Receive News & Ratings for Crinetics Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Crinetics Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
